Characterisation of AD Animal Models: Building In Vivo Tools to Assess Next-Generation AD Therapeutics

Supported by:

19 July 2016



Preclinical development of drug candidates for Alzheimer’s disease (AD) takes multiple different paths; animal models are indispensable tools to support diverse preclinical drug development programs. Charles River performs in-house evaluations employing several mouse models of AD using a range of up-to-date in vivo approaches with an emphasis on the translatability of findings in mice to changes that are observed in human patients.

This webinar highlights imaging as well as cognitive and physiological testing of these AD models and is useful for scientists engaged in drug discovery in the field of neurodegeneration.


  • Robert Hodgson, PhD, Director, Science R&D, Charles River
  • Maksym Kopanitsa, PhD, Head of Electrophysiology, Charles River

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.